Status:
UNKNOWN
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Institute on Aging (NIA)
Rutgers University
Conditions:
Gout
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alter...
Detailed Description
This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translati...
Eligibility Criteria
Inclusion
- Please see https://docs.google.com/spreadsheets/d/1N3IVoirGdWS7OiKiOWWgPHhgsSxX7SWDIhpeeZ-Ft7c/edit?usp=sharing or Appendix A for full code and algorithm definitions.
- Medicare timeframe: 2007 to 2017 (end of data availability).
- 1\. No prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date
- 2\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
Exclusion
- 1\. Prior history of dementia measured anytime prior to cohort entry date
- 2\. No prior history of gout recorded in the 365 days prior to cohort entry date
- 3\. Prior history of nursing home admission in the 365 days prior to the cohort entry date
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
294878 Patients enrolled
Trial Details
Trial ID
NCT04746989
Start Date
February 1 2021
End Date
December 31 2023
Last Update
July 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02120